Sirnaomics to Present at TIDES Europe 2021
and SUZHOU BIOBAY, China, Nov. 16, 2021 /PRNewswire/ -- Sirnaomics, Inc. , a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announcedthat it will be presenting positive results from a Phase 2a clinical study of the company's lead drug candidate, STP705, for treatment of squamous cell skin cancer in situ(nonmelanoma skin cancer) at the 2021 TIDES Europe event.
- and SUZHOU BIOBAY, China, Nov. 16, 2021 /PRNewswire/ -- Sirnaomics, Inc. , a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announcedthat it will be presenting positive results from a Phase 2a clinical study of the company's lead drug candidate, STP705, for treatment of squamous cell skin cancer in situ(nonmelanoma skin cancer) at the 2021 TIDES Europe event.
- The hybrid conference is taking place digitally and in person at the Sheraton Brussels Airport Hotel in Belgium from November 15-17, 2021.
- Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is aDelawarecorporation headquartered inGaithersburg, Maryland, with subsidiaries in Suzhou andGuangzhou, China.
- Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline.